DiaMedica Therapeutics (DMAC) Total Non-Current Liabilities (2018 - 2026)
DiaMedica Therapeutics' (DMAC) quarterly Total Non-Current Liabilities came in at $69000.0 in Q2 2026, down 62.5% on a YoY basis from $184000.0 in Q2 2025, and down 28.87% quarter-over-quarter from $97000.0 in Q1 2026.
Powered by 
Analysis
DiaMedica Therapeutics (DMAC) Total Non-Current Liabilities (2018 - 2026) Analysis & Trends
DiaMedica Therapeutics (DMAC) has reported Total Non-Current Liabilities for 9 consecutive years, with $69000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Total Non-Current Liabilities fell 62.5% year-over-year to $69000.0; the trailing twelve-month figure through Jun 2026 stood at $69000.0 (down 62.5% YoY), and the FY2025 full-year result was $128000.0, down 45.99% from the prior year.
- Total Non-Current Liabilities fell to $69000.0 in Q2 2026 per DMAC's latest filing, from $97000.0 in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $420000.0 in Q3 2022 and bottomed at $7000.0 in Q2 2022.
- Historically, Total Non-Current Liabilities has averaged $231277.8 across 5 years, with a median of $250000.0 in 2024.
- The widest YoY moves for Total Non-Current Liabilities: up 13233.33% in 2022, down 72.73% in 2022.
- Over 5 years, Total Non-Current Liabilities stood at $400000.0 in 2022, then declined by 20.75% to $317000.0 in 2023, then retreated by 25.24% to $237000.0 in 2024, then slumped by 45.99% to $128000.0 in 2025, then plunged by 46.09% to $69000.0 in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $69000.0, $97000.0, and $128000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.38 Bn | 192.39 Bn | 7.24 Bn | 81.11 Bn |
| 2 | Gilead Sciences | 180.22 Bn | 177.04 Bn | 6.22 Bn | 36.04 Bn |
| 3 | Vertex Pharmaceuticals | 131.28 Bn | 123.42 Bn | 2.84 Bn | 5.92 Bn |
| 4 | Regeneron Pharmaceuticals | 81.96 Bn | 73.97 Bn | 3.93 Bn | 7.74 Bn |
| 5 | Argenx Se | 60.49 Bn | 55.30 Bn | 1.37 Bn | 40.00 Mn |
| 6 | Moderna | 53.90 Bn | 48.76 Bn | 52.00 Mn | 3.92 Bn |
| 7 | Alnylam Pharmaceuticals | 33.41 Bn | 30.11 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | 12.42 Bn |
| 9 | Roivant Sciences | 29.08 Bn | 29.08 Bn | 1.16 Mn | 378.37 Mn |
| 10 | DiaMedica Therapeutics | 341.42 Mn | 341.42 Mn | - | 69,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 69,000.00 |
| Mar 31, 2026 | 97,000.00 |
| Dec 31, 2025 | 128,000.00 |
| Sep 30, 2025 | 157,000.00 |
| Jun 30, 2025 | 184,000.00 |
| Mar 31, 2025 | 211,000.00 |
| Dec 31, 2024 | 237,000.00 |
| Sep 30, 2024 | 263,000.00 |
| Jun 30, 2024 | 288,000.00 |
| Mar 31, 2024 | 294,000.00 |
| Dec 31, 2023 | 317,000.00 |
| Sep 30, 2023 | 340,000.00 |
| Jun 30, 2023 | 361,000.00 |
| Mar 31, 2023 | 381,000.00 |
| Dec 31, 2022 | 400,000.00 |
| Sep 30, 2022 | 420,000.00 |
| Jun 30, 2022 | 7,000.00 |
| Mar 31, 2022 | 9,000.00 |
| Dec 31, 2021 | 3,000.00 |
| Sep 30, 2021 | 4,000.00 |